药品注册申请号:211785
申请类型:ANDA (仿制药申请)
申请人:MYLAN TECHNOLOGIES
申请人全名:MYLAN TECHNOLOGIES INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 2MG BASE;EQ 0.5MG BASE No No AB 2020/04/17 2020/04/17 Prescription
002 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 4MG BASE;EQ 1MG BASE No No AB 2020/04/17 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/06/12 SUPPL-13(补充) Approval Labeling STANDARD
2024/06/12 SUPPL-8(补充) Approval Labeling STANDARD
2024/06/12 SUPPL-4(补充) Approval Labeling STANDARD
2024/06/12 SUPPL-1(补充) Approval Labeling STANDARD
2024/03/20 SUPPL-7(补充) Approval REMS
2022/12/16 SUPPL-5(补充) Approval REMS
2022/05/03 SUPPL-2(补充) Approval REMS
2020/04/17 ORIG-1(原始申请) Approval STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE 剂型/给药途径:FILM;BUCCAL, SUBLINGUAL 规格:EQ 2MG BASE;EQ 0.5MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
022410 001 NDA SUBOXONE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 2MG BASE;EQ 0.5MG BASE Prescription Yes No AB 2010/08/30 INDIVIOR
205299 001 ANDA BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 2MG BASE;EQ 0.5MG BASE Prescription No No AB 2018/06/14 DR REDDYS LABS SA
205954 001 ANDA BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 2MG BASE;EQ 0.5MG BASE Prescription No No AB 2019/01/24 ALVOGEN
211785 001 ANDA BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 2MG BASE;EQ 0.5MG BASE Prescription No No AB 2020/04/17 MYLAN TECHNOLOGIES
活性成分:BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE 剂型/给药途径:FILM;BUCCAL, SUBLINGUAL 规格:EQ 4MG BASE;EQ 1MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
022410 003 NDA SUBOXONE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 4MG BASE;EQ 1MG BASE Prescription Yes No AB 2012/08/10 INDIVIOR
205806 001 ANDA BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 4MG BASE;EQ 1MG BASE Prescription No No AB 2018/06/14 DR REDDYS LABS SA
205954 002 ANDA BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 4MG BASE;EQ 1MG BASE Prescription No No AB 2019/01/24 ALVOGEN
211785 002 ANDA BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL EQ 4MG BASE;EQ 1MG BASE Prescription No No AB 2020/04/17 MYLAN TECHNOLOGIES
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database